Pieris Pharmaceuticals Valuation
| PIRS Stock | USD 16.77 0.84 5.27% |
At this time, the company appears to be overvalued. Pieris Pharmaceuticals holds a recent Real Value of $14.15 per share. The prevailing price of the company is $16.77. Our model determines the value of Pieris Pharmaceuticals from analyzing the company fundamentals such as Operating Margin of (0.57) %, return on equity of -0.8, and Shares Outstanding of 1.32 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Pieris Pharmaceuticals' valuation include:
Price Book 1.3614 | Enterprise Value -4.2 M | Enterprise Value Ebitda (1.47) | Price Sales 1.0611 | Enterprise Value Revenue 1.7644 |
Overvalued
Today
Please note that Pieris Pharmaceuticals' price fluctuation is not too volatile at this time. Calculation of the real value of Pieris Pharmaceuticals is based on 3 months time horizon. Increasing Pieris Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Pieris stock is determined by what a typical buyer is willing to pay for full or partial control of Pieris Pharmaceuticals. Since Pieris Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pieris Stock. However, Pieris Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 16.77 | Real 14.15 | Target 7.0 | Hype 16.77 | Naive 16.64 |
The intrinsic value of Pieris Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Pieris Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Pieris Pharmaceuticals helps investors to forecast how Pieris stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pieris Pharmaceuticals more accurately as focusing exclusively on Pieris Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Pieris Pharmaceuticals' intrinsic value based on its ongoing forecasts of Pieris Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Pieris Pharmaceuticals' closest peers.
Pieris Pharmaceuticals Cash |
|
Pieris Valuation Trend
Pieris Pharmaceuticals' real value is important for investors to make better decisions and a more accurate overall view of Pieris Pharmaceuticals' financial worth over time. Using both Pieris Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Pieris Revenue by Product
Pieris Pharmaceuticals Total Value Analysis
Pieris Pharmaceuticals is at this time projected to have valuation of (4.22 M) with market capitalization of 21.14 M, debt of 11.92 M, and cash on hands of 80.94 M. The negative valuation of Pieris Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Pieris Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(4.22 M) | 21.14 M | 11.92 M | 80.94 M |
Pieris Pharmaceuticals Investor Information
About 53.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.36. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pieris Pharmaceuticals recorded a loss per share of 12.11. The entity had not issued any dividends in recent years. The firm had 1:80 split on the 23rd of April 2024. Based on the key indicators related to Pieris Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Pieris Pharmaceuticals may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Pieris Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Pieris Pharmaceuticals has an asset utilization ratio of 110.68 percent. This implies that the Company is making $1.11 for each dollar of assets. An increasing asset utilization means that Pieris Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Pieris Pharmaceuticals Ownership Allocation
The market capitalization of Pieris Pharmaceuticals is $21.14 Million. Over half of Pieris Pharmaceuticals' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.Pieris Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 42.81 M. Net Loss for the year was (24.54 M) with loss before overhead, payroll, taxes, and interest of (27.08 M).About Pieris Pharmaceuticals Valuation
The stock valuation mechanism determines Pieris Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Pieris Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Pieris Pharmaceuticals. We calculate exposure to Pieris Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pieris Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 1 M | 958.5 K | |
| Pretax Profit Margin | (0.57) | (0.60) | |
| Operating Profit Margin | (0.70) | (0.73) | |
| Net Loss | (0.57) | (0.60) | |
| Gross Profit Margin | 0.02 | 0.02 |
Pieris Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Pieris Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.1 M |
Pieris Pharmaceuticals Current Valuation Indicators
Pieris Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Pieris Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Pieris Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Pieris Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Pieris Pharmaceuticals' worth.Additional Tools for Pieris Stock Analysis
When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.